KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Teva Pharmaceutical Industries (TEVA) Net Income (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Net Income readings, the most recent being $370.0 million for Q1 2026.

On a quarterly basis, Net Income rose 68.18% to $370.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 billion, a 217.3% increase, with the full-year FY2025 number at $1.4 billion, up 171.58% from a year prior.
Net Income hit $370.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $470.0 million in the prior quarter.
In the past five years, Net Income ranged from a high of $519.0 million in Q1 2024 to a low of -$1.3 billion in Q4 2022.
Median Net Income over the past 5 years was $64.0 million (2022), compared with a mean of -$140.6 million.
Biggest five-year swings in Net Income: plummeted 1286.59% in 2022 and later skyrocketed 305.14% in 2024.
Teva Pharmaceutical Industries' Net Income stood at -$1.3 billion in 2022, then surged by 134.93% to $466.0 million in 2023, then tumbled by 159.01% to -$275.0 million in 2024, then soared by 270.91% to $470.0 million in 2025, then decreased by 21.28% to $370.0 million in 2026.
The last three reported values for Net Income were $370.0 million (Q1 2026), $470.0 million (Q4 2025), and $432.0 million (Q3 2025) per Business Quant data.